Zydus Cadila bags USFDA nod for anti-arrhythmic drug Propafenone Hydrochloride ER Capsules
Ahmedabad: Drug major, Zydus Cadila, has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules).
Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 315 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.